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Abstract
Background: Oliguria is associated with a decreased kidney- and organ perfusion, leading to organ damage and
increased mortality. While the effects of correcting oliguria on renal outcome have been investigated frequently,
whether urine output is a modifiable risk factor for mortality or simply an epiphenomenon remains unclear. We
investigated whether targeting urine output, defined as achieving and maintaining urine output above a predefined
threshold, in hemodynamic management protocols affects 30-day mortality in perioperative and critical care.
Methods: We performed a systematic review with a random-effects meta-analyses and meta-regression based on
search strategy through MEDLINE, EMBASE and references in relevant articles. We included studies comparing
conventional fluid management with goal-directed therapy and reporting whether urine output was used as target or
not, and reporting 30-day mortality data in perioperative and critical care.
Results: We found 36 studies in which goal-directed therapy reduced 30-day mortality (OR 0.825; 95% CI 0.684-0.
995; P = 0.045). Targeting urine output within goal-directed therapy increased 30-day mortality (OR 2.66; 95% CI 1.
06-6.67; P = 0.037), but not in conventional fluid management (OR 1.77; 95% CI 0.59-5.34; P = 0.305). After
adjusting for operative setting, hemodynamic monitoring device, underlying etiology, use of vasoactive
medication and year of publication, we found insufficient evidence to associate targeting urine output with a
change in 30-day mortality (goal-directed therapy: OR 1.17; 95% CI 0.54-2.56; P = 0.685; conventional fluid
management: OR 0.74; 95% CI 0.39-1.38; P = 0.334).
Conclusions: The principal finding of this meta-analysis is that after adjusting for confounders, there is
insufficient evidence to associate targeting urine output with an effect on 30-day mortality. The paucity of direct
data illustrates the need for further research on whether permissive oliguria should be a key component of fluid
management protocols.
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Background
Textbooks and guidelines frequently recommend urine
output as a parameter to guide fluid administration, since
decreased organ perfusion may decrease urine output in
an attempt to maintain intravascular volume [1–3]. How-
ever, a suboptimal hemodynamic status is not always the
cause of oliguria. In recent years, the concept of an associ-
ation between intraoperative urine output and postopera-
tive acute kidney injury has been challenged [4–6]. As a
result, advocacy for permissive oliguria has increased, for
example to include permissive oliguria in the early recov-
ery after surgery (ERAS) protocols [7–9].
Our group has previously published meta-analyses
concerning the effects of targeting urine output on acute
renal failure or acute kidney injury [10, 11]. A frequent
remark on these meta-analyses was that while targeting
urine output may not have an effect on preventing acute
kidney injury, there is increasing evidence that reduced
urine output is a risk factor for mortality [12–15]. Espe-
cially in critically ill patients, the occurrence and severity
of oliguria is associated with an increase in mortality.
Whether the association between urine output and out-
come is due to a causal relation or rather an epiphenom-
enon is yet to be determined. Nevertheless, fluids and
vasoactive medication are often administered to patients
with a decrease in urine output to guarantee and main-
tain adequate perfusion. However, whether urine output
is a useful target for fluid management remains doubtful,
especially when direct measures related to cardiac out-
put and oxygen delivery are available.
We hypothesize that including urine output as a target
does not decrease 30-day mortality in perioperative and
critical care. This study aims to investigate whether in-
cluding urine output as a target in fluid management
protocols reduces 30-day mortality in perioperative and
critical care.
Methods
Search strategy
We conducted a systematic literature search of MED-
LINE by using PubMed (1966 – present) and EMBASE
(1980 – present). There were no studies directly investi-
gating the effect on 30-day mortality by urine output as
fluid management target in a perioperative or critical
care protocol. Therefore, to determine the effect of urine
output as a target, all studies comparing goal-directed
therapy (GDT) and conventional fluid management
(CFM) and reporting within 30-day mortality were iden-
tified. The last search was performed in May 2016. No
limits for publication date or language were used. Add-
itional file 1: Table S1 and Table S2, shows the strategy
for the MEDLINE and EMBASE database. The ‘related
articles’ function in PubMed provided us with the oppor-
tunity to identify eligible studies that were not found by
the main search queries. All references of the identified
articles and review articles were hand searched to avoid
missing relevant trials. We screened the title and ab-
stract of the studies found in the databases to determine
whether GDT was compared to CFM and to establish
whether mortality was reported. We used the full text of
the article in case of uncertainty about the therapy or
mortality.
Study selection
The search was performed by two authors (E.Z., M.E.).
Disagreements were resolved by consensus or if neces-
sary by a third author (ABJG). We included randomized
controlled trials during perioperative or critical care into
our main analysis, whereas observational studies have
been collected and are reported in Additional file 1.
Animal studies, pediatric trials (<18 years), articles writ-
ten in another language than English, studies unavailable
as full-text, and studies in which mortality data was not
clearly described were excluded. Due to the difficulty of
using urine output as a parameter after administration
of diuretics, the use of diuretic drugs to increase urine
output was not allowed during the intervention period.
Therefore, studies using diuretics during the interven-
tion period were excluded. Although a full description of
the protocol was not required, the hemodynamic targets
in the CFM arm had to be clearly reported. We excluded
studies which described the CFM arm as ‘standard treat-
ment’ without further elaboration. Quality assessment
was performed using the Cochrane Collaboration’s tool
for assessing risk of bias [16].
Definitions
Goal-directed therapy was defined as any hemodynamic
optimization strategy in the perioperative and critical
care setting, utilizing parameters related to cardiac out-
put and oxygen delivery, either exclusively or in combin-
ation with classical parameters such as blood pressure
and heart rate, irrespective of the device or method used
to measure these parameters. Urine output as a target
was defined as achieving and maintaining urine output
using fluids and vasoactive medication above a prede-
fined threshold. We did not redefine the urine output
thresholds and used the thresholds as set by the re-
spective studies. No distinction was made between iso-
lated oliguria or urine output in combination with
other hemodynamic parameters. We defined mortality
as death by all causes within 30 days after inclusion. In
case mortality was reported as ‘intensive care mortality’
or ‘in-hospital mortality’, we used the respective length
of stay data to determine the survival duration. Studies
in which more than 75% of the patients were admitted
for less than 30 days were considered for reporting 30-
day mortality.
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Data collection
Two authors (E.Z., M.E.) extracted the following vari-
ables: total study population, size of GDT arm, size of
CFM arm, type of patients, timing of the intervention
period, definition of GDT and CFM, urine output target
criteria, total amount of fluids infused per study arm, in-
traoperative and postoperative urine output data, treat-
ment targets in both study arms, definition of mortality
and number of deaths.
Data synthesis
All selected studies were divided into three groups for
the main forest plot based on whether oliguria reversal
was included as a target in a study protocol: trials com-
paring GDT and CFM in which both the GDT protocol
and the CFM protocol did not include urine output as a
target, articles in which urine output was only targeted
in the CFM protocol, and articles in which GDT and
CFM treatment arms both included urine output as tar-
get. We analyzed whether there was a difference in 30-
day mortality between the two treatment arms and in
the targeting urine output subsets. A funnel plot was
conducted to identify asymmetry. If publication bias was
detected, possible missing studies were identified by
using the ‘trim and fill’ method.
To investigate the effect of targeting urine output in
CFM and in GDT on mortality, a meta-regression model
was performed to estimate a regression equation with
30-day mortality as outcome and the use of urine output
as a target as a variable for GDT and CFM. This meta-
regression model was then adjusted with study setting,
hemodynamic monitoring device used, underlying eti-
ology, use of vasoactive medication and year of publica-
tion as covariates in the regression equation. The year of
publication variable was centered on the mean year of
publication, which was 2008.
Due to the various threshold values used as the urine
output target, we performed a sensitivity analysis exclud-
ing studies utilizing a urine output target different from
the conventional standard of 0.5 ml/kg/h. This sensitiv-
ity analysis was performed for both the meta-analysis as
well as the meta-regression analysis.
Statistical analysis
For each study odds ratios (OR) and 95% confidence in-
tervals (CI) were calculated, based on their sample sizes
of the GDT and CFM and the reported mortality in
those treatment arms. All meta-analyses were conducted
as random effect meta-analyses in R (version 3.2.1) using
the metafor package [17, 18]. The Sidik-Jonkman estima-
tor was used in combination with Knapp & Hartung ad-
justment to improve estimates of the heterogeneity
variance due to the low number of studies included [19,
20]. In studies with a count of zero in one of the
treatment arms, 0.5 was added to all frequencies. Het-
erogeneity between the trials was analyzed using the I2
statistic and interpreted using thresholds as defined in
the Cochrane Handbook [21]. A trial sequence analysis
was performed to account for random error. Optimal
sample size – i.e., information size – was determined
using alpha = 0.05 and power of 0.80 for a relative risk
reduction of 25%. Due to the Knapp-Hartung adjust-
ment utilizing a t-distribution, we converted the t-value
to a z-score using a nominal p-value approach for the
trial sequence analysis. Quality of evidence was assessed
using the GRADE system [22]. We used a random-
effects meta-regression model with targeting urine out-
put, study setting, hemodynamic monitoring device
used, underlying etiology, use of vasoactive medication
and year of publication as covariates and fluid manage-
ment protocol (GDT or CFM) as the inner grouping
variable and study as the outer grouping variable to test
the effect of the moderators on 30-day, using a bivariate
approach which has been described earlier [23]. This
method resulted in separate regression equations for the
30-day mortality risk in GDT and in CFM. For the sensi-
tivity analysis for studies with a urine output target of
0.5 ml/kg/h, we repeated the meta-analysis and meta-
regression analysis. Odds ratios were considered statisti-
cally significant when their 95% CI did not include 1.00
and the corresponding P-value was less than 0.05.
Results
Our search strategy resulted in 1435 articles. A total of
326 remained after excluding duplicates and irrelevant
articles. After removing studies which met our exclusion
criteria, 83 articles remained. An additional 41 studies
were excluded based on the usage of diuretics, or the ab-
sence of a description of the hemodynamic parameters
in the CFM arm (Fig. 1). Table 1 shows the characteris-
tics of the remaining 36 randomized controlled trials.
Thirteen studies [24–36] did not target urine output
in either GDT or CFM; seven studies [37–43] only
targeted urine output in the CFM protocol; and six-
teen studies [44–59] targeted urine output in both
protocols. Hemodynamic monitoring devices and pa-
rameters used in the included studies are reported in
Table 2. The amount of fluids infused during GDT
and CFM in each study is reported in Additional file
1: Table S3. The risk of bias assessment is shown in
Fig. 2. Of the 23 studies which included urine output
as a target, fifteen studies had a threshold of 0.5 ml/
kg/h (Table 2). The data of the limited studies in
which the amount of urine output was reported are
collected in Additional file 1: Table S4. The data on
the six observational studies [60–65] are reported in
Additional file 1: Table S5 and Table S6.
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Meta-analysis
Because there was no direct data on the effect of target-
ing urine output on mortality, we first pooled the studies
comparing GDT with CFM based on the presence of
urine output as a target in either fluid management pro-
tocols. Overall, GDT was associated with a decrease in
30-day mortality (OR 0.83; 95% CI 0.68 to 1.00; P = 0.04;
I2 = 28%; N = 36) (Fig. 3). However, there was insufficient
evidence for a decrease in 30-day mortality due to GDT
in all the subgroups. The heterogeneity was low to
moderate. The funnel plot is shown in Additional file 2:
Figure S1. A slight asymmetry was detected; and identifi-
cation of eight possible missing studies altered the point
estimate (OR 0.75; 95% CI 0.56 to 1.00; P = 0.05; I2 =
32.8%). The trial sequential analysis is shown in
Additional file 3: Figure S2. Despite reaching statistical
significance, the required information size of 7400 was
not reached and the cumulative Z-score did not cross
the monitoring boundaries. This suggests that the results
for the beneficial effects of GDT on mortality in this
meta-analysis are inconclusive, and the quality of evi-
dence – as assessed by GRADE – is limited.
Meta-regression analysis
To assess the effects of urine output as a fluid manage-
ment target from the available data, we performed a
meta-regression analysis to estimate a regression line for
GDT and CFM with targeting urine output as a second-
ary variable. There was insufficient evidence to suggest
that targeting urine output influences 30-day mortality in
a CFM protocol (OR 1.77; 95% CI 0.59-5.34; P = 0.305).
However, targeting urine output increased 30-day mortal-
ity when using GDT (OR 2.66 95% CI 1.06-6.67; P =
0.037). After adjusting for study setting, hemodynamic
monitoring device, underlying etiology, use of vasoactive
medication and year of publication (Table 3), there was in-
sufficient evidence to associate targeting urine output with
an effect on 30-day mortality when using a CFM protocol
(OR 0.74; 95% CI 0.39-1.38; P = 0.334) and a GDT proto-
col (OR 1.17; 95% CI 0.54-2.56; P = 0.685).
Sensitivity analysis
In the sensitivity analysis excluding studies with a urine
output threshold different from the conventional stand-
ard of 0.5 ml/kg/h in the targeting urine output group,
GDT was associated with a decrease in 30-day mortality
(OR 0.78; 95% CI 0.63 to 0.97; P = 0.03; I2 = 31.8%; N =
29, Additional file 4: Figure S3). In the bivariate meta-
regression analysis, we found insufficient evidence to
suggest that targeting urine output with a threshold of
0.5 ml/kg/h was associated with an increase in 30-day
mortality when using a CFM protocol (OR 1.90; 95% CI
0.56 to 6.50; P = 0.300) and in a GDT protocol (OR 2.46;
95% CI 0.80 – 7.59; P = 0.114). After adjusting for covar-
iates (Table 4), targeting urine output was not associated
with a change in 30-day mortality when using a CFM
protocol (OR 0.89; 95% CI 0.41 - 1.91; P = 0.756) and a
GDT protocol (OR 1.08; 95% CI 0.48 – 2.44; P = 0.852).
Discussion
The principal finding of this meta-analysis is that while
GDT might decrease 30-day mortality, including urine
output as a target may increase 30-day mortality. How-
ever, after adjusting for confounders, there is insufficient
evidence to associate targeting urine output with an ef-
fect on 30-day mortality. Additionally, using the com-
mon urine output threshold of 0.5 ml/kg/h, there was
insufficient evidence to suggest that targeting urine out-
put affected 30-day mortality. Considering our previous
findings that targeting urine output does not prevent
acute renal failure [10, 11], our current finding adds fur-
ther evidence to strongly reconsider the use of urine
output as a fluid management target.
Our data shows that GDT is associated with an overall
decrease in 30-day mortality, although barely reaching
significance. This is partially in agreement with previ-
ously published meta-analyses on GDT and mortality.
Fig. 1 Flow chart of study selection. CFM: conventional fluid
management; RCT: randomized controlled trial
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Table 1 Characteristics of studies included
Study Total number Type of patient Timing Mortality follow up
Not targeting urine output
in either protocol
Sinclair 1997 [24] 40 Orthopedic intra 30 days
Polonen 2000 [25] 393 Cardiac post 28 days
Rhodes 2002 [26] 201 Critically ill ICU 28 days
Pearse 2005 [27] 122 High risk post 28 days
Szakmany 2005 [28] 40 Abdominal Intra 3 days postoperative
Wakeling 2005 [29] 128 Abdominal intra 30 days
Forget 2010 [30] 86 Abdominal intra 30 days
WenKui 2010 [31] 214 Abdominal intra, post 30 days
Cecconi 2011 [32] 40 Orthopedic intra 28 days
Challand 2012 [33] 236 Abdominal Intra 30 days
Bartha 2013 [34] 149 Orthopedic intra 30 days
Bisgaard 2013 [35] 70 Abdominal intra, post 30 days
Lai 2015 [36] 221 Abdominal Intra 30 days
Targeting urine output
only in CFM
Bishop 1995 [37] 115 Trauma post, ICU in-hospital (95% < 15 days)
McKendry 2004 [38] 174 Cardiac post 30 days
Benes 2010 [39] 120 High Risk intra 30 days
Mayer 2010 [40] 60 High Risk Intra in-hospital (95% < 30 days)
McKenny 2013 [41] 101 Abdominal Intra 30 days
Zakhaleva 2013 [42] 74 Abdominal Intra 30 days
Osawa 2016 [43] 126 Cardiac Intra, post 30 days
Targeting urine output
in both protocols
Shoemaker 1988 [44] 88 High Risk intra, post in-hospital (95% < 29 days)
Boyd 1993 [45] 107 High Risk pre, intra, post, ICU 28 days
Gattinoni 1995 [46] 762 High Risk ICU 30 days
Lobo 2000 [47] 37 High Risk intra, post 28 days,
Rivers 2001 [48] 263 Sepsis ICU 28 days
Chytra 2007 [49] 162 Trauma ICU n-hospital (75% <29 days)
Donati 2007 [50] 135 Abdominal Intra in-hospital (95% < 30 days)
Kapoor 2008 [51] 27 Cardiac post in-hospital (95% < 13 days)
Senagore 2009 [52] 43 Abdominal Intra 2 days
Jammer 2010 [53] 241 Abdominal intra 30 days
Jansen 2010 [54] 348 Critically ill ICU 28 days
Jhanji 2010 [55] 135 Abdominal post, ICU in-hospital (75% < 28 days)
Bisgaard 2013 [56] 40 Vascular Intra, post 30 days
Zheng 2013 [57] 60 Abdominal Pre, intra, post in-hospital (75% <27 days)
Peng 2014 [58] 80 Orthopedic Intra in-hospital (95% <28 days)
Correa-Gallego 2015 [59] 135 Abdominal Intra, post 30 days
Pre preoperative, intra intraoperative, post postoperative, ICU intensive care unit
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Table 2 Hemodynamic monitoring used in selected studies
Study Device Hemodynamic targets Urine output threshold Intervention
Not targeting urine output in either protocol
Sinclair 1997 [24] esophageal Doppler SV colloids
Polonen 2000 [25] SvO2, Lactate fluids, dobutamine,
vasoactive medication
Rhodes 2002 [26] PAC PAWP fluid boluses, vasoactive
agents
Pearse 2005 [27] LiDCO plus SV, DO2I colloid, dopexamine
Szakmany 2005 [28] PiCCO ITBVI crystalloid, colloid
Wakeling 2005 [29] esophageal Doppler SV colloids
Forget 2010 [30] Masimo pulse oximeter PVI colloids, vasoactive
medication
WenKui 2010 [31] Lactate crystalloids, colloids,
dopamine, ephedrine
Cecconi 2011 [32] FloTrac/Vigileo SV colloids, vasoactive
medication, dobutamine
Challand 2012 [33] esophageal Doppler SV colloid
Bartha 2013 [34] LiDCO SV, DO2I fluids, vasoactive
medication
Bisgaard 2013 [35] LiDCO SVI colloids, dobutamine,
vasoactive medication
Lai 2015 [36] LiDCO SVV Colloids
Targeting urine output only in CFM
Bishop 1995 [37] PAC DO2I, VO2I, CI 30-50 ml/h volume, dobutamine
McKendry 2004 [38] esophageal Doppler SI no specific goal
mentioned
colloids, blood, vasoactive
medication
Benes 2010 [39] FloTrac/Vigileo SVV 0.5 ml/kg/h colloids, dobutamine
Mayer 2010 [40] FloTrac/Vigileo CI, SVI 0.5 ml/kg/h crystalloids, colloids,
norepinephrine, dobutamine,
vasodilators
McKenny 2013 [41] esophageal Doppler SV 0.5 ml/kg/h colloids
Zakhaleva 2013 [42] esophageal Doppler SV, SVR, CO, FTc 0.5-1.0 ml/kg/h colloids
Osawa 2016 [43] LIDCO CI, SVI 0.5 ml/kg/h crystalloid, dobutamine
Targeting urine ouput in both protocols
Shoemaker 1988 [44] PAC Hct, PvO2, PAP, SVR, PWP, PVR, DO2,
VO2
30 mL/h crystalloids, colloids,
vasoactive medication
Boyd 1993 [45] PAC DO2I 0.5 mL/kg/h gelatin, dopexamine
Gattinoni 1995 [46] PAC CI or SvO2 0.5 mL/kg/h fluids, vasoactive medication
Lobo 2000 [47] PAC DO2 0.5 mL/kg/h fluids, dobutamine
Rivers 2001 [48] computerized
spectrophotometer
ScvO2, MAP 0.5 mL/kg/h crystalloid dobutamine,
blood transfusions
Chytra 2007 [49] esophageal Doppler SV, FTc 1 mL/kg/h colloids
Donati 2007 [50] SvO2, O2ERe 0.5 mL/kg/h fluids, dobutamine
Kapoor 2008 [51] FloTrac/Vigileo CVP, SVV 1 mL/kg/h colloids, dopamine
or other inotropes
Senagore 2009 [52] esophageal Doppler SV 0.5 mL/kg/h colloid
Jammer 2010 [53] ScvO2 0.5 mL/kg/h crystalloids, colloid
Jansen 2010 [54] CeVOX Lactate, ScvO2 0.5 mL/kg/h fluids, vasodilator therapy
Jhanji 2010 [55] LiDCO SV 25 mL/h fluids, dopexamine
Bisgaard 2013 [56] LiDCO DO2I, SVI 0.5–1.0 mL/kg/h colloid, dobutamine
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While one meta-analysis in surgical patients reported
that GDT was associated with a decrease in mortality
[66], another meta-analysis in surgical patients found no
such effect [67]. The difference in mortality between
these two meta-analyses may be due to studies published
after the publication of the meta-analysis by Brienza et
al. [66]. The disagreement between the meta-analysis by
Corcoran et al. [67] and our meta-analysis may be due
to three reasons: the inclusion of newer studies, the
addition of critical care studies, and the follow-up period
for mortality. Additionally, the meta-analysis by Zhang
et al. showed that patients with severe sepsis or septic
shock receiving GDT had a similar risk of mortality
compared with those in the control group [68]. Never-
theless, as the optimal information size metric suggests,
the currently available pool of studies may be insufficient
to conclusively state any effect of GDT on mortality.
This meta-analysis supports the hypothesis that oli-
guria is likely an epiphenomenon rather than a modifi-
able risk factor. In a perioperative setting, low urine
output is common in the first 24 h after surgery and in
the absence of other issues it does not reliably reflect
fluid status [5]. Moreover, urine output is influenced by
factors other than the hemodynamic status [69, 70]. Sur-
gical trauma and physical stress in critical illness cause
the release of neuro-hormonal factors which influence
glomerular filtration pressure or water reabsorption in
the collecting duct, such as catecholamines, arginine
vasopressin and the renin-angiotensin-aldosterone
system. While these neuro-hormonal factors are also up-
regulated in hypovolemia resulting in oliguria, the peri-
operative or critical care setting itself does promote the
occurrence of oliguria. Additionally, anesthetic tech-
niques and medication can affect neuro-hormonal fac-
tors as well as vasomotor tone. Moreover, using urine
output to guide fluid management is inherently flawed
due to the delayed response. Evaluating the urinary re-
sponse to a fluid challenge is generally possible after at
least 15-30 min, and is limited by the lack of a clear
dose-response relationship. In contrast, hemodynamic
parameters such as cardiac output are dynamic variables
which are influenced within a short interval after a fluid
challenge is given and for most variables a dose-
response relationship has been given. Thus, the primary
cause of oliguria may not be affected by fluid administra-
tion, or may already have been resolved by acting on an-
other target.
In light of this, the use of permissive oliguria has
already been advocated in ERAS protocols, primarily to
avoid excess fluid loading [7]. In patients managed by
hemodynamic targets with a better correlation to fluid
status, the occurrence of oliguria due to hemodynamic
causes is unlikely, which favors the exclusion of urine
output as a target for fluid resuscitation. Considering
this, the current paradigm that urine output reflects
renal injury and – perhaps indirectly – increases mortal-
ity needs to be revisited [12, 14]. In most – if not all –
cases, oliguria is most likely an epiphenomenon of an
underlying problem. A recent study showed that after
adjusting for confounders while intraoperative urine out-
put was not associated with postoperative morbidity,
total intraoperative fluid intake and postoperative fluid
boluses for hypotension and low urine output were asso-
ciated with an increase in postoperative morbidity [59].
This strongly suggests that urine output should not be a
target in a fluid management protocol to improve
outcome.
This meta-analysis has several important limitations.
The main limitation is the various sources of heterogen-
eity. The I2 statistic showed low to moderate heterogen-
eity in most analyses. However, considering the different
hemodynamic targets, fluid types, vasopressor use, mon-
itoring devices, underlying etiologies, clinical settings
and mortality follow-up used in these studies, assuming
that the heterogeneity is as low as suggested by the I2
statistic would be imprudent. Because some studies did
not report data of fluids infused as a statistical measure
and data regarding the amount of urine output were
rarely reported at all, further analysis of these data
points was not possible. Despite the use of a random-
Table 2 Hemodynamic monitoring used in selected studies (Continued)
Zheng 2013 [57] FloTrac/Vigileo CI, SVI, SV 0.5 mL/kg/h balanced salt solution,
colloid, dopamine /
norepinephrine,
nitroglycerin / ephedrine
Peng 2014 [58] FloTrac/Vigileo SVV 0.5 mL/kg/h Crystalloid, colloid,
Correa-Gallego 2015
[59]
FloTrac/Vigileo SVV 25 mL/h for 2
consecutive hours
Crystalloid, colloid, albumin
bolus infusions
PAC pulmonary artery catheter, PAC+ pulmonary artery catheter with supranormal hemodynamic targets, pre preoperative, intra intraoperative, post postoperative,
ICU intensive care unit, ITBVI intrathoracic blood volume index, SV stroke volume, DO2I oxygen delivery index, PAOP pulmonary artery occlusion pressure, CI
cardiac index, CO cardiac output, SVR systemic vascular resistance, SVI systemic vascular index, PCWP pulmonary capillary wedge pressure, DO2 oxygen delivery,
PVI pleth variability index, GEDI global end-diastolic volume index, ELVI extravascular lung water index, SvO2 mixed venous oxygen saturation, PAWP pulmonary
artery wedge pressure, FTc corrected flow time, PAWP pulmonary artery wedge pressure, SVV stroke volume variation, VO2I oxygen consumption index, SI stroke
index, O2ERe oxygen extraction estimate, ScvO2 central venous oxygen saturation, CVP central venous pressure, PvO2 venous oxygen pressure, PAP pulmonary
artery pressure, PWP pulmonary wedge pressure, PVR pulmonary vascular resistance, Hct hematocrit, VO2 oxygen consumption, UO urine output
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effects model and a bi- and multivariate approach to
a meta-regression analysis, the effects of between-
trial differences are most likely not completely taken
into account [19, 20]. Since our findings are based
on between-trial statistical analyses, given the large
differences between the included studies, the in-
terpretation of these findings – even after adjusting
for operative setting, underlying etiology and other
confounders - should be done with care. Unde-
rstandably, given the absence of trials primarily in-
vestigating the effects of urine output as a target, to
account for all the possible sources of heterogeneity
within the currently available literature would be im-
practical and the inability to do so is currently an
inevitable limitation. However, after acknowledging
this limitation, our findings are currently the only
assessment of the effects of targeting urine output
on mortality, and are supported by the observations
from various trials [6, 59].
Another important limitation is the low number of
studies given the available literature on GDT. The po-
tential for robust conclusions by using meta-regression
is limited by the number of studies [71]. However, to en-
sure that heterogeneity was limited as much as possible,
several of the larger - and perhaps more convincing –
trials were excluded. The three recent large studies -
ARISE, PROCESS and PROMISE - were not included
in this meta-analysis, due to meeting our exclusion
criterion of vague CFM protocols [72–74]. While their
exclusion may limit the generalization of our findings,
the strict inclusion and exclusion criteria removes bias
caused by some of the heterogeneity. Given that our
main objective was to assess the effect of targeting
urine output on 30-day mortality, removing as many
sources of heterogeneity as possible strengthens our
findings. Similarly, despite the absence of these large
trials, the mortality rate in most studies is close to the
estimated 30-day mortality rate in elective – high risk –
surgery (~7%) and critical care (~15%) [75–77]. Add-
itionally, a slight asymmetry was found in the funnel
plot, and after applying the ‘trim and fill’ method, the
effect size of eight possible missing studies were added
to the analysis. In combination with the trail sequential
analysis, this suggests insufficient evidence to support a
difference in 30-day mortality between GDT and CFM,
despite the analysis in Fig. 3, and illustrates the dep-
endence on adequate sample size to establish definite
conclusions.
Fig. 2 Risk of bias assessment. Risk of bias assessment performed
with the Cochrane Collaboration tool [16]. Because there are two
studies by Bisgaard et al. published in 2013, 1 marks reference [35],
and 2 marks reference [56]. Gray circle: low risk of bias; blank: unclear
risk of bias; white circle: high risk of bias
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Fig. 3 Forest plot of 36 studies reporting 30-day mortality when comparing goal-directed therapy with conventional fluid management. +: mor-
tality follow-up was shorter than 28 days. *: mortality reported as in-hospital mortality. **: mortality data extracted from Kaplan-Meier curve. GDT:
goal-directed therapy; CFM: conventional fluid therapy; OR: odds ratio; CI: confidence interval
Table 3 Meta-regression model with 30-day mortality as outcome
for conventional and goal-directed fluid therapy
Variable CFM GDT
Targeting urine output 0.74 (0.39-1.38) 1.17 (0.54-2.56)
Intensive Care setting (reference)
Intraoperative setting 0.15 (0.08-0.28) 0.12 (0.05-0.28)
Postoperative setting 0.06 (0.02-0.15) 0.12 (0.03-0.51)
Transpulmonary thermodilution
(reference)
Esophageal Doppler 0.67 (0.21-2.11)
Pulmonary artery catheter 1.27 (0.25-6.35)
Other monitoring devices 0.79 (0.27-2.27)
Other etiologies (reference)
Abdominal 0.32 (0.15-0.69) 0.76 (0.32-1.77)
High risk 2.13 (0.94-4.81) 2.19 (0.74-6.51)
Inotropic use 1.40 (0.72-2.69) 1.01 (0.40-2.53)
Publication year a 0.97 (0.93-1.02) 1.00 (0.91-1.10)
aPublication year was inputted as the years from the mean publication
year (2008)
Data reported as odds ratio and 95% confidence interval
Table 4 Meta-regression model of sensitivity analysis with 30-day
mortality for conventional and goal-directed fluid therapy
Variable CFM GDT
Targeting urine output 0.56 (0.29-1.11) 0.68 (0.34-1.36)
Intensive Care setting (reference)
Intraoperative setting 0.16 (0.08-0.30) 0.14 (0.08-0.24)
Postoperative setting 0.07 (0.03-0.16) 0.17 (0.05-0.57)
Transpulmonary thermodilution
(reference)
Esophageal Doppler 0.61 (0.23-1.60)
Pulmonary artery catheter 1.80 (0.51-6.33)
Other monitoring devices 0.21 (0.07-0.63)
Other etiologies (reference)
Abdominal 0.48 (0.21-1.10) 1.14 (0.54-2.38)
High risk 2.36 (0.99-5.67) 1.19 (0.61-2.30)
Inotropic use 1.43 (0.67-3.07) 1.15 (0.47-2.81)
Publication year a 0.95 (0.9-1.00) 0.95 (0.88-1.03)
The sensitivity analysis excluded studies in which the urine output threshold
was not 0.5 ml/kg/h
aPublication year was inputted as the years from the mean publication year
(2008). Data reported as odds ratio and 95% confidence interval
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Conclusion
In conclusion, based on the currently available literature,
we found that while GDT might decrease 30-day mortal-
ity, including urine output as a target may increase 30-
day mortality. However, the principal finding of this
meta-analysis is that after adjusting for confounders,
there is insufficient evidence to associate targeting urine
output with an effect on 30-day mortality. This suggests
that oliguria is not a modifiable risk factor for mortality,
and using diuresis to guide fluid management may not
affect survival. However, the paucity of direct data illus-
trates the need for further research on whether oliguria is
just an epiphenomenon and whether ‘permissive oliguria’
should be a key component of fluid management
protocols.
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